Search research articles
Contact Us
Filters
Showing results (1-10 of 369) with videos related to
Page
of 37
Sort By:
Cancers
|
March 10, 2022
Activation of Investigator-Initiated Clinical Trials with a Pharmaceutical for Cancer Patients before and after Post-Millennial Changes of Regulations in Germany and Europe
Wolfgang E Berdel
Cancers
|
April 3, 2021
Unintended Regulatory Caused Early Death-A Difficult Endpoint in Cancer Patient Care and Treatment
Wolfgang E Berdel
Cancer Cell
|
March 5, 2004
c-maf in multiple myeloma: an oncogene enhancing tumor-stroma interactions
Joachim Kienast, Wolfgang E Berdel
Molecular Pharmaceutics
|
February 8, 2017
Immunoprotein-Mediated siRNA Delivery
Nicole Bäumer, Wolfgang E Berdel, Sebastian Bäumer
Pediatric Hematology and Oncology
|
September 23, 2011
New targets and targeted drugs for the treatment of cancer: an outlook to pediatric oncology
Claudia Rossig, Heribert Juergens, Wolfgang E Berdel
Current Drug Targets
|
February 20, 2007
Oncogenic signaling in acute myeloid leukemia
Christian H Brandts, Wolfgang E Berdel, Hubert Serve
Plos One
|
September 26, 2015
Expression of Interleukin-1 and Interleukin-1 Receptors Type 1 and Type 2 in Hodgkin Lymphoma
Elisabeth Oelmann, Harald Stein, Wolfgang E Berdel, et al.
Onkologie
|
December 8, 2007
Gemtuzumab ozogamicin (mylotarg) for the treatment of acute myeloid leukemia--ongoing trials
Beate Gleissner, Richard Schlenk, Martin Bornhäuser, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
|
December 25, 2009
Lymphangiogenesis in cancer: current perspectives
Rüediger Liersch, Christoph Biermann, Rolf M Mesters, et al.
International Journal of Hematology
|
September 9, 2005
Signal transduction of oncogenic Flt3
Chunaram Choudhary, Carsten Müller-Tidow, Wolfgang E Berdel, et al.
Page
of 37
Search research articles
Search
Showing results (1-10 of 369) with videos related to
Sort By:
Page
of 37
Cancers
|
March 10, 2022
Activation of Investigator-Initiated Clinical Trials with a Pharmaceutical for Cancer Patients before and after Post-Millennial Changes of Regulations in Germany and Europe
Wolfgang E Berdel
Cancers
|
April 3, 2021
Unintended Regulatory Caused Early Death-A Difficult Endpoint in Cancer Patient Care and Treatment
Wolfgang E Berdel
Cancer Cell
|
March 5, 2004
c-maf in multiple myeloma: an oncogene enhancing tumor-stroma interactions
Joachim Kienast, Wolfgang E Berdel
Molecular Pharmaceutics
|
February 8, 2017
Immunoprotein-Mediated siRNA Delivery
Nicole Bäumer, Wolfgang E Berdel, Sebastian Bäumer
Pediatric Hematology and Oncology
|
September 23, 2011
New targets and targeted drugs for the treatment of cancer: an outlook to pediatric oncology
Claudia Rossig, Heribert Juergens, Wolfgang E Berdel
Current Drug Targets
|
February 20, 2007
Oncogenic signaling in acute myeloid leukemia
Christian H Brandts, Wolfgang E Berdel, Hubert Serve
Plos One
|
September 26, 2015
Expression of Interleukin-1 and Interleukin-1 Receptors Type 1 and Type 2 in Hodgkin Lymphoma
Elisabeth Oelmann, Harald Stein, Wolfgang E Berdel, et al.
Onkologie
|
December 8, 2007
Gemtuzumab ozogamicin (mylotarg) for the treatment of acute myeloid leukemia--ongoing trials
Beate Gleissner, Richard Schlenk, Martin Bornhäuser, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
|
December 25, 2009
Lymphangiogenesis in cancer: current perspectives
Rüediger Liersch, Christoph Biermann, Rolf M Mesters, et al.
International Journal of Hematology
|
September 9, 2005
Signal transduction of oncogenic Flt3
Chunaram Choudhary, Carsten Müller-Tidow, Wolfgang E Berdel, et al.
Page
of 37